Quarterlytics / Healthcare / Biotechnology / Altimmune, Inc. / FY2022 Annual Report

Altimmune, Inc.
Annual Report 2022

ALT · NASDAQ Healthcare
Claim this profile
Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Employees 59
← All annual reports
FY2022 Annual Report · Altimmune, Inc.
Loading PDF…
Page 1 of 2 
Appendix 4E 
Preliminary Final Report 
 
Name of entity 
Analytica Limited 
ABN  
12 006 464 866 
 
 
1. Reporting Period 
 
Report for the financial year end 
30 June 2022 
Previous corresponding reporting period  
30 June 2021 
 
2. Results for announcement to the market 
 
$ 
Percentage 
increase/(decrease) over 
previous corresponding 
period 
Revenue from ordinary activities 
285,726 
(64) 
Profit/(loss) from ordinary activities after 
tax attributable to members 
(2,238,553) 
(48) 
Net profit/(loss) for the period attributable 
to members 
(2,238,553) 
(48) 
Dividends 
Amount per security 
Franked amount per security 
Final dividend 
Nil 
Nil 
Interim dividend 
Nil 
Nil 
Record date for determining entitlements to 
dividend 
Not applicable 
Brief explanation of any of the figures reported above necessary to enable the figures to be 
understood 
 
 
3. Income 
Statement 
Refer to Attachment A  
4. Balance Sheet 
Refer to Attachment A  
5. Statement of 
Changes in 
Equity 
Refer to Attachment A  
 
6. Cash Flow 
Statement 
Refer to Attachment A  
 
 

Page 2 of 2 
7. Dividends 
Date dividend is payable 
Not applicable 
Record date to determine entitlement to the dividend 
Not applicable 
Amount per security 
Not applicable 
Total dividend 
Not applicable 
Amount per security of foreign sourced dividend or distribution 
Not applicable 
Details of any dividend reinvestment plans in operation 
Not applicable 
The last date for receipt of an election notice for participation in any 
dividend reinvestment plans 
Not applicable 
 
8. Statement of retained earnings 
Consolidated Entity 
 
2022 
2021 
Balance at the beginning of the year 
(106,192,017) 
(104,726,230) 
Net profit attributable to members of the parent 
entity 
(2,238,553) 
(1,507,406) 
Transfer from option reserve 
810,569 
41,619 
Balance at end of the year 
(107,620,001) 
(106,192,017) 
 
 
 
9. Net tangible assets per security 
 
 
 
Current period 
Previous 
corresponding 
period 
Net tangible asset backing per ordinary 
security 
($0.0005)  
($0.00045) 
 
 
 
10. Details of entities over which control has been gained or lost 
during the period 
Not applicable 
 
 
 
11. Details of associated and joint venture entities 
Name of associate or joint venture entity 
% Securities held 
PeriCoach Pty Ltd 
100 
Analytica Operations Pty Ltd 
100 
Analytica Export ME Pty Ltd 
100 
 

Analytica Limited 
ABN 12 006 464 866 
ANNUAL REPORT 
YEAR ENDED 30 JUNE 2022